# Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale

> **NCT01122108** · PHASE4 · COMPLETED · sponsor: **Louisville Metabolic and Atherosclerosis Research Center** · enrollment: 42 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cholestyramine
- **DRUG:** Colesevelam HCl

## Key facts

- **NCT ID:** NCT01122108
- **Lead sponsor:** Louisville Metabolic and Atherosclerosis Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2010-10-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01122108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01122108, "Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01122108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*